Skip to main content

Counterfeit Version of Adderall Unsafe, Ineffective, FDA Warns


May 30, 2012 — A counterfeit version of Adderall (Teva Pharmaceutical Industries) 30 mg tablets being sold on the Internet is unsafe, ineffective, and potentially harmful, the US Food and Drug Administration (FDA) warns.
The FDA's preliminary laboratory tests show that the counterfeit tablets contain the wrong active ingredients. Adderall contains dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amephtamine sulfate. In contrast, the counterfeit medication was found to contain tramadol and acetaminophen.
Currently on the FDA's drug shortage list, Adderall is in short supply owing to active pharmaceutical ingredient supply issues. Teva continues to release product as it becomes available. The FDA warns that "consumers should be extra cautious when buying their medicines from online sources. Rogue Web sites and distributors may especially target medicines in short supply for counterfeiting."
The counterfeit Adderall tablets are round, white, and do not have any markings. The FDA has posted a link to photos of the counterfeit pills and notes that any product that resembles the tablets or packaging and claims to be Adderall 30 mg pill should be considered counterfeit.
In contrast, authentic Adderall 30 mg tablets produced by TEVA are round and orange/peach in color, with "dp" embossed on one side of the tablet and "30" on the other side. Teva's Adderall 30 mg tablets are packaged only in a 100-count bottle with the National Drug Code (NDC) 0555-0768-02 listed.
The Adderall 30 mg product may be counterfeit if:
  1. The product comes in a blister package.
  2. There are misspellings on the package.
    • "NDS" appears instead of "NDC."
    • "Aspartrte" appears instead of "Aspartate."
    • "Singel" appears instead of "Single."
  3. The tablets are white in color, round in shape, and are smooth.
  4. The tablets have no markings on them.
Anyone who believes they have the counterfeit version of Teva's Adderall 30 mg tablets should not take or should stop taking the product. Consumers should talk to their healthcare professional about their condition and options for treatment.
Consumers and healthcare professionals are encouraged to report adverse events or side effects from the suspect counterfeit Adderall to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
  • Complete and submit the report online: www.fda.gov/MedWatch/report.htm.
  • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.
Consumers who believe they have received counterfeit Adderall should contact the FDA's Office of Criminal Investigations (OCI) at 800-551-3989 or http://www.fda.gov/OCI.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volum...
Post a Comment
Read more

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n...
4 comments
Read more